Literature DB >> 25177478

Characterization of diabetes risk factors in patients prescribed chronic statin therapy.

William M King1, Joseph J Saseen2, Sarah L Anderson3.   

Abstract

OBJECTIVE: Determine the incidence of major diabetes risk factors over time in patients prescribed chronic statin therapy.
METHODS: Retrospective observational chart review of adult patients without diabetes in primary care who initiated statin therapy between 2005 and 2010. Presence of diabetes risk factors were determined 1 year prior to statin initiation and continued up to a maximum of 7 years. Diabetes risk factors included impaired fasting glucose, body mass index (BMI) ≥30 kg/m(2), hemoglobin A1c >6% and metabolic syndrome. Descriptive statistics were used to describe the incidence of diabetes risk factors over time.
RESULTS: A total of 98 patients met study criteria; mean age was 57 ± 13 years, 43% were men and 71% self-identified as Caucasian/white. Mean baseline values were A1c of 5.97%, fasting glucose of 104 mg/dl and BMI of 28 kg/m(2). There were zero diabetes risk factors over time in 54% ± 7% of patients. The incidence over time of 1 risk factor was 25 ± 9%, 2 risk factors was 17 ± 5% and 3 risk factors was 3 ± 2%. A total of 12 patients were diagnosed with type 2 diabetes during the course of the study period.
CONCLUSION: The incidence of diabetes risk factors did not change over time in an ambulatory adult population prescribed chronic statin therapy. Larger population studies assessing the incidence of and change in diabetes risk factors in patients on chronic statin therapy may help assess the association between statin therapy and presence of such risk factors.

Entities:  

Keywords:  3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors; diabetes risk factors; incident type 2 diabetes; statins

Year:  2014        PMID: 25177478      PMCID: PMC4131502          DOI: 10.1177/2040622314530460

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  12 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

Review 2.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

Review 4.  Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.

Authors:  Huseyin Naci; Jasper Brugts; Tony Ades
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-07-09

5.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

Authors:  Annie L Culver; Ira S Ockene; Raji Balasubramanian; Barbara C Olendzki; Deidre M Sepavich; Jean Wactawski-Wende; Joann E Manson; Yongxia Qiao; Simin Liu; Philip A Merriam; Catherine Rahilly-Tierny; Fridtjof Thomas; Jeffrey S Berger; Judith K Ockene; J David Curb; Yunsheng Ma
Journal:  Arch Intern Med       Date:  2012-01-09

6.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

7.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Authors:  Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford
Journal:  Lancet       Date:  2010-02-16       Impact factor: 79.321

Review 8.  Statins for the primary prevention of cardiovascular disease.

Authors:  Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

9.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Authors:  Paul M Ridker; Aruna Pradhan; Jean G MacFadyen; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2012-08-11       Impact factor: 79.321

10.  Risk of incident diabetes among patients treated with statins: population based study.

Authors:  Aleesa A Carter; Tara Gomes; Ximena Camacho; David N Juurlink; Baiju R Shah; Muhammad M Mamdani
Journal:  BMJ       Date:  2013-05-23
View more
  1 in total

1.  Association of statin use and stress-induced hyperglycemia in patients with acute ST-elevation myocardial infarction.

Authors:  Chen Yan; Ma Qin; Yang S Juan; Li Y Tao; Gao M Dong; Zeng Zechun; Yang X Chun; Cong H Liang; Liu Yin; Meng Kang
Journal:  JRSM Cardiovasc Dis       Date:  2016-04-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.